The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-15 and is reviewed periodically as new material appears.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Birds have evolved a variety of mating behaviours, with the peacock tail being perhaps the most famous example of sexual selection and the Fisherian runaway. Commonly occurring sexual dimorphisms such as size and colour differences are energetically costly attributes that signal competitive breeding situations. Many types of avian sexual selection have been identified; intersexual selection, also known as female choice; and intrasexual competition, where individuals of the more abundant sex compete with each other for the privilege to mate. Sexually selected traits often evolve to become more pronounced in competitive breeding situations until the trait begins to limit the individual's fitness. Conflicts between an individual fitness and signalling adaptations ensure that sexually selected ornaments such as plumage colouration and courtship behaviour are "honest" traits. Signals must be costly to ensure that only good-quality individuals can present these exaggerated sexual ornaments and behaviours.
Spectrophotometry: This is a widely used method for measuring the concentration and purity of a DNA sample. Spectrophotometry measures the absorbance of a sample at different wavelengths, typically at 260 nm and 280 nm. The ratio of absorbance at 260 nm and 280 nm is used to determine the purity of the DNA sample. Gel electrophoresis: This technique is used to visualize and compare the size and integrity of DNA samples. The DNA is loaded onto an agarose gel and then subjected to an electric field, which causes the DNA to migrate through the gel. The migration of the DNA can be visualized using ethidium bromide, which intercalates into the DNA and fluoresces under UV light. Fluorometry: Fluorometry is a method to determine the concentration of nucleic acids by measuring the fluorescence of the sample when excited by a specific wavelength of light. Fluorometry uses dyes that specifically bind to nucleic acids and have a high fluorescence intensity. PCR: Polymerase Chain Reaction (PCR) is a technique that amplifies a specific region of DNA, it is also used as a QC method by amplifying a small fragment of the DNA, if the amplification is successful, it means the extracted DNA is of good quality and it's not degraded. Qubit Fluorometer: The Qubit Fluorometer is an instrument that uses fluorescent dyes to measure the concentration of DNA and RNA in a sample. It is a quick and sensitive method that can be used to determine the concentration of DNA samples.
protic Also protogenic. (of a chemical species) Capable of acting as a proton donor; readily generating or yielding free protons (H+) in solution. Protic species may therefore be considered strongly or weakly acidic in the sense of a Brønsted–Lowry acid.
With its large size and geographic variety, the United States includes most climate types. East of the 100th meridian, the climate ranges from humid continental in the north to humid subtropical in the south. The western Great Plains are semi-arid. Many mountainous areas of the American West have an alpine climate. The climate is arid in the Southwest, Mediterranean in coastal California, and oceanic in coastal Oregon, Washington, and southern Alaska. Most of Alaska is subarctic or polar. Hawaii, the southern tip of Florida and U.S. territories in the Caribbean and Pacific are tropical. The United States receives more high-impact extreme weather incidents than any other country. States bordering the Gulf of Mexico are prone to hurricanes, and most of the world's tornadoes occur in the country, mainly in Tornado Alley. Due to climate change, extreme weather has become more frequent in the U.S. in the 21st century, with three times the number of reported heat waves compared to the 1960s. Since the 1990s, droughts in the American Southwest have become more persistent and more severe. The regions considered as the most attractive to the population are the most vulnerable.
== See also == Resonance-enhanced multiphoton ionization Rydberg ionization spectroscopy Photoionization Atmospheric-pressure laser ionization Radiometric dating Electron excitation Tunable lasers Cosmochemistry
Sources: en.wikipedia.org
has to be changed compared to the simple SIR model.) Early models of this type have been used to model the spread of the black death in Europe. Extensions of this model have been used to incorporate, e.g., effects of nonpharmaceutical interventions such as social distancing.
The Grainyhead-like (Grhl) gene family is a group of highly conserved transcription factors, which work to regulate the expression of specific target genes. Grainyhead (Grh) was originally identified in Drosophila as being implicated within development through its role of regulating numerous genetic pathways. While Drosophila has only one Grh gene, there are three homologues currently known across other species (Grhl1-3). It appears that all members of the Grhl gene family are involved in epidermal barrier integrity, including its formation and repair, and are tightly regulated to prevent physical defects. The Grhl family of genes are found in a range of organisms, from humans to fish and fungi, and all have similar roles to each other in regards to the developmental processes that they have a role in regulating. This could indicate that the Grhl genes could be one of the earliest genes to arise within our genome, providing vital functions for survival of an early common ancestor.
where the carbon-12 nucleus used in the first reaction is regenerated in the last reaction. After the two positrons (emitted by beta-plus decay) annihilate with two ambient electrons producing an additional 2.04 MeV, the total energy released in one cycle is 26.73 MeV; in some texts, authors are erroneously including the positron annihilation energy in with the Q-value for beta-decay and then neglecting the equal amount of energy released by annihilation, leading to possible confusion. All values are calculated with reference to the Atomic Mass Evaluation 2003. The limiting (slowest) reaction in the CNO-I cycle is the proton capture on 147N. In 2006 it was experimentally measured down to stellar energies, revising the calculated age of globular clusters by around 1 billion years. The neutrinos emitted in beta decay will have a spectrum of energy ranges, because although momentum is conserved, the momentum can be shared in any way between the positron and neutrino, with either emitted at rest and the other taking away the full energy, or anything in between, so long as all the energy from the Q-value is used. The total momentum received by the positron and the neutrino is not great enough to cause a significant recoil of the much heavier daughter nucleus and hence, its contribution to kinetic energy of the products, for the precision of values given here, can be neglected. Thus the neutrino emitted during the decay of nitrogen-13 can have an energy from zero up to 1.20 MeV, and the neutrino emitted during the decay of oxygen-15 can have an energy from zero up to 1.73 MeV.
Late-onset Pompe disease (GSD-II) also has calf hypertrophy and hypothyroidism as comorbidities. Poor diet and malabsorption diseases (such as celiac disease) may lead to malnutrition of essential vitamins necessary for glycogen metabolism within the muscle cells. Malnutrition typically presents with systemic symptoms, but in rare instances can be limited to myopathy. Vitamin D deficiency myopathy (also known as osteomalic myopathy due to the interplay between vitamin D and calcium) results in muscle weakness, predominantly of the proximal muscles; with muscle biopsy showing abnormal glycogen accumulation, atrophy of type II (fast-twitch/glycolytic) muscle fibres, and diminished calcium uptake by the sarcoplasmic reticulum (needed for muscle contraction). Although Vitamin D deficiency myopathy typically includes muscle atrophy, rarely calf muscle hypertrophy has been reported. Exercise-induced, electrically silent, muscle cramping and stiffness (transient muscle contractures or "pseudomyotonia") are seen not only in GSD types V, VII, IXd, X, XI, XII, and XIII, but also in Brody disease, Rippling muscle disease types 1 and 2, and CAV3-related hyperCKemia (Elevated serum creatine phosphokinase). Unlike the other myopathies, in Brody disease the muscle cramping is painless. Like GSD types II, III, and V, a pseudoathletic appearance of muscle hypertrophy is also seen in some with Brody disease and Rippling muscle disease.
Homes built on a crawl space may benefit from a radon collector installed under a "radon barrier" (a sheet of plastic that covers the crawl space). For crawl spaces, the EPA states that "[a]n effective method to reduce radon levels in crawl space homes involves covering the earth floor with a high-density plastic sheet. A vent pipe and fan are used to draw the radon from under the sheet and vent it to the outdoors. This form of soil suction is called submembrane suction, and when properly applied is the most effective way to reduce radon levels in crawl space homes." Computational fluid dynamics (CFD) modelling has been used to quantify the performance of sub-slab air chamber systems under both depressurization and forced-air ventilation configurations. Models validated against experimental data from a real building show that depressurization systems reduce indoor radon concentrations by 45–90% relative to a sealed chamber, with smaller buildings achieving the greatest reductions and efficiency gains diminishing at higher extraction flow rates. Forced-air ventilation systems, by contrast, can generate overpressure within the chamber if the inlet flow exceeds the outlet capacity, which promotes radon ingress and may increase indoor concentrations. These findings support the optimization of mitigation system design by balancing radon reduction against construction complexity and energy consumption.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.